The decision between CDMO outsourcing and in-house manufacturing is becoming a strategic question for biotechnology companies as development programs move toward commercial scale. Building internal capacity can provide greater control over process knowledge, scheduling, and supply, but it also creates substantial capital, utilization, and regulatory commitments. Outsourcing reduces the need for upfront infrastructure while providing access to established manufacturing capabilities, yet introduces dependence on external capacity and technology-transfer timelines.

Regulatory implications also matter: the FDA’s ICH Q5E guidance states that manufacturing changes, including changes to the manufacturing site, may require extensive analytical and functional comparability assessment to demonstrate that product quality, safety, and efficacy remain unaffected.

For biotech sponsors, the right strategy therefore depends less on whether CDMO or in-house manufacturing is inherently better and more on when ownership creates enough economic and strategic value to justify the investment.

Also read: Why Pharmaceutical Research Is Becoming More Collaborative Than Ever

Capital Discipline Separates the Biotechnology Industry’s Winners from Its Cash-Burners

Building a commercial-scale biologics facility runs anywhere from 200 million to over a billion dollars, depending on modality and scale. That figure rarely matters to a Series B company with eighteen months of runway. It matters intensely to a sponsor approaching Phase 3 with a molecule projected to generate nine-figure annual revenue. Capital intensity only justifies fixed-asset ownership once probability-adjusted revenue clears that bar. Every other variable in this framework follows from that first filter.

When Outsourcing Becomes the Lower-Risk Option

Certain program characteristics push the calculus decisively toward a CDMO partnership:

• Modality novelty: viral vectors and ADCs demand process expertise few internal teams have built
• Capital velocity: runway measured in quarters rules out a nine-figure facility buildout
• Platform volatility: programs likely to pivot format need flexible capacity, rather than fixed assets
• Regulatory geography: filings spanning FDA, EMA, and PMDA favor partners with existing site approvals

At Scale, Ownership Can Outperform Outsourcing

Alira Health’s 2026 Biologics Contract Manufacturing Report notes that the ten largest CDMOs hold 55 percent of total market value, and fewer than fifteen offer commercial-scale GLP-1 peptide manufacturing worldwide. That concentration cuts both ways: it rewards sponsors who lock in slots early, and it punishes late movers who assumed capacity would stay available. Past a certain volume, roughly where annual CDMO spend approaches what amortized facility ownership would cost, sponsors gain more from owning the asset than from competing for someone else’s reactor schedule.

Sponsors Can Split Manufacturing Across Internal and External Capacity

Pure build or pure buy is turning into a false choice. Sponsors increasingly split the value chain: drug substance manufactured internally where the process is proprietary, fill-finish and packaging outsourced where speed matters more than control. Others dual-source the same molecule across two CDMOs specifically to spread supply risk, a lesson reinforced by current pressure on Chinese-origin manufacturing relationships. The real question shifts from CDMO versus in-house to which steps in the chain deserve ownership and which deserve flexibility.

How to Quantify the Build-vs-Buy Decision

Five variables make a workable scoring model: technical complexity of the modality, capital available against runway, timeline to first commercial batch, breadth of regulatory filings required, and strategic value of retaining process know-how. Score each from one to five. Weight capital and timeline heaviest for early-stage sponsors; weight technical complexity and process control heaviest for platform companies. Programs scoring above threshold on ownership value should build. Everything below it should partner, with the score revisited at every major inflection point, Phase 2 to Phase 3, or first commercial approval.

Frequently Asked Questions

When Does In-House Manufacturing Become More Cost-Effective Than a CDMO?

In-house manufacturing can become more cost-effective when annual CDMO spending reaches a sustained level that approaches the amortized cost of owned capacity. The threshold varies by modality, facility scale, utilization, and regulatory requirements, so sponsors should compare multi-year total cost rather than per-batch pricing alone.

Can a Biotech Company Transition From a CDMO to In-House Manufacturing?

Yes. The transition typically requires technology transfer, process validation, comparability studies, regulatory submissions, and qualification of the new manufacturing site. Planning the transition during Phase 2 can reduce disruption and give the sponsor time to address CMC and regulatory requirements before commercial production.